Venus Remedies Ltd Share Price Today - Venus Remedies Ltd Stock Price Live NSE/BSE

Venus Remedies Ltd

NSE: VENUSREM BSE: 526953

₹861.70

(9.99%)

Sat, 21 Mar 2026, 03:43 am

MTF 5xInvest in Venus Remedies Ltd with 5x Leverage Buy with MTF

Market Cap10.49B

PE Ratio15.09

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Venus Remedies Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
1146.29
Net Profit
45.31
P/B
0.71
Sector P/E
32.08
P/E
8.84
EV/EBITDA
3.41
Debt/Equity (Industry)
0.47
Interest Cover (Industry)
5.19
ROCE (Industry)
14.14
RONW (Industry)
11.70
ROE
7.16
ROCE
10.93
Debt/Equity
0.04
EPS (TTM)
57.09
Dividend Yield
0
Book Value
444.61
Interest Cover
862.13

Analysis

all

Pros

Whilst loss making Venus Remedies has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -52.4% per year.
Whilst loss making Venus Remedies has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
Debt is well covered by operating cash flow (31.8%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 1.3x debt.
Venus Remedies's cash and other short term assets cover its long term commitments.

Cons

Unable to calculate sustainability of dividends as Venus Remedies has not reported any payouts.
Unable to evaluate Venus Remedies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Venus Remedies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Venus Remedies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Venus Remedies is making a loss, therefore interest payments are not well covered by earnings.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	41.76	41.76	41.76	41.76	41.76
FII	2.26	1.86	2.24	1.34	1.11
DII	1.03	0.75	0.11	0	0
Public	54.96	55.63	55.89	56.90	57.13
Government	0	0	0	0	0

Technical Analysis

RSI

60.15

MACD

40.77

50 DMA

764.91

200 DMA

593.49

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1077.35	901.40	786.90	725.45	610.95	549.50	373.55
Fibonacci	901.40	834.19	792.66	725.45	658.24	616.71	549.50
Camarilla	720.79	704.66	688.53	725.45	656.27	640.14	624.01

Pivots Level: Classic

+351.90

1077.35

+175.95

901.40

+61.45

786.90

725.45

Pivot Point

LTP: 868.25

-114.50

610.95

-175.95

549.50

-351.90

373.55

Moving Average

SMAEMA

Period

Value

10-EMA
853.51
20-EMA
816.24
30-EMA
796.71
50-EMA
771.55
100-EMA
713.22
200-EMA
619.71

Announcement Date	Purpose	Action	Ex Date
29 Jan 2026	board-meetings	Quarterly Results
10 Nov 2025	board-meetings	Quarterly Results
08 Jul 2025	agm
21 Aug 2024	agm
13 Aug 2024	agm	Annual General Meeting	17 Sept 2024
17 Jul 2023	agm	Annual General Meeting	18 Aug 2023
15 Jul 2023	agm
25 Jul 2022	agm
11 Jul 2022	agm	Annual General Meeting	17 Aug 2022
17 Aug 2021	agm

Venus Remedies Ltd

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Sun Pharmaceutical Industries Ltd

Venus Remedies Ltd About

Venus Remedies is one of the handful player in pharmaceutical sector to launch injectables globally. It has world-class manufacturing facilities in Panchkula and Baddi (in India), and research and development centre under the name of Venus Medicine Research Centre.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1989

Headquarters

CEO

Pawan Chaudhary

Employees

Contact

Website

http://www.venusremedies.com

investorgrievance@venusremedies.com; complianceoff

Phone

Location

S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101

Year	History
2019	Venus announces deal with Cipla for its patented product Elores for Indian Territory.
2021	Venus Remedies launched its full-fledged Consumer Healthcare Division. Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India.
2022	Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. Venus remedies wins ambitionbox best places to work award. Venus Remedies Limited has been Great Place to Work Certified.
2023	Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering ''Organ-on-a-Chip'' Research Model. Venus Remedies Limited Honored with Best Working Conditions Award 2022. Venus Remedies launched flagship R&D drug Elores in Oman. Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from four more countries. Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities. Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.
2024	Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.

Client Name	Order Side	QTY	Avg Price	Date
PRADEEP KUMAR JAIN	Sell	135966	422.77	30 May 2025
MC JAIN INFOSERVICES PRIVATE LIMITED	Sell	90000	292.7	21 Mar 2025
SAMYAK ENTERPRISES	Buy	90000	292.7	21 Mar 2025
CRONY VYAPAR PVT LTD	Buy	75190	356.91	06 Feb 2025
PARTH INFIN BROKERS PVT LTD	Sell	114490	353.88	06 Feb 2025
CRONY VYAPAR PVT LTD	Sell	50190	352.6	06 Feb 2025
PARTH INFIN BROKERS PVT LTD	Buy	125195	354.83	06 Feb 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	68957	376.56	13 Jun 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	68957	377.21	13 Jun 2024
SOCIETE GENERALE	Buy	66838	380.25	24 Jan 2024

Venus Remedies Ltd News

Venus Remedies promoter group merger announced

Venus Remedies Limited disclosed that promoter group entities Sunev Pharma Solutions and Spine Software Systems have approved a merger scheme, with Sunev's 17.21% stake to transfer to Spine.

02 Mar 2026

co actions results

Venus Remedies Q3 Net Profit Rises 30.6% to ₹256M

Venus Remedies reports consolidated net profit of ₹256 million in Q3, up from ₹196 million year-on-year. Revenue increased marginally to ₹1.8 billion from ₹1.77 billion in the same period last year.

29 Jan 2026

co actions results

Venus Remedies Gets ₹11.77 Cr PLI Scheme Funding

Venus Remedies receives ₹11.77 crore under the PLI scheme, adding to its previous ₹10 crore disbursement, strengthening its pharmaceutical manufacturing capabilities.

22 Jan 2026

stocks

Venus Remedies Board Meet on Jan 29 for Q3FY26 Results

Venus Remedies Limited has scheduled a board meeting on January 29, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025.

19 Jan 2026

stocks

Venus Remedies corrects UDIN for Q2FY26 results

Venus Remedies Limited updates UDIN for consolidated financial results after clerical duplication error in statutory auditor reports for quarter ended September 30, 2025.

13 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800